These figures were presented by Eder Gatti, director of the National Immunization Program, during a conference at the 28th National Symposium of the Brazilian Society of Immunizations, as reported by Agencia Brasil.

According to Gatti, the country has supplied over 11.8 million doses of the vaccine against the disease—7.6 million for the first dose and 4.2 million for the second one.

The vaccine, Qdenga—produced by the Japanese pharmaceutical company Takeda—requires two doses, administered three months apart, to complete the vaccination regimen. Gatti emphasized the importance of expanding coverage before the Southern Hemisphere summer, a period when dengue cases typically rise in Brazil.

The influence of the El Nino climate event could further intensify the situation during this season, the news outlet noted.

“Vaccinating adolescents—who often lack a clear perception of risk—is quite challenging. In the case of dengue, the ideal approach is to vaccinate during the off-season, when incidence is lower, ensuring they are already protected by the time the virus begins to circulate more widely,” Gatti explained.

The immunization campaign, led by the Unified Health System (SUS) which began in the municipalities most severely hit by the disease, was gradually expanded nationwide, targeting children and adolescents aged 10 to 14.

jdt/arm/ft/dsa